Hyotae Kim

Hyotae Kim

Senior Research Associate | Biostatistics & Bioinformatics

Publications

Statistical Methodology

  1. Kim, H., Siddiqui, N. Y., Karstens, L., and Ma, L. (2026). “A negative binomial latent factor model for paired microbiome sequencing data.” BMC Bioinformatics, 27(1), 45. [Code].

  2. Kim, H. and Kottas, A. (2022). “Erlang mixture modeling for Poisson process intensities.” Statistics and Computing, 32, 3. [Code].

  3. Xiao, S., Kottas, A., Sansó, B., and Kim, H. (2021). “Nonparametric Bayesian modeling and estimation for renewal processes.” Technometrics, 63(1), 100–115.

  4. Kim, H., Jo, S., and Choi, T. (2015). “Performance comparison of random number generators based on Adaptive Rejection Sampling.” Journal of the Korean Data & Information Science Society, 26(3), 593–610.

Manuscripts

  1. Kim, H. and Halabi, S. (2026). “A Two-Stage Bayesian Framework for Combining Clinical Trial and Real-World Data: Model-Based Clustering and Hierarchical Modeling.” (Under review). [PDF].

  2. Kim, H. and Ma, L. (2026). “An Exponential Scale Mixture Model for Metatranscriptomics Data with Application to Inflammatory Bowel Disease.” (Under revision). [Preprint].

  3. Kim, H. and Kottas, A. (2026). “Bayesian Nonparametric Marked Hawkes Processes for Earthquake Modeling.” (Under revision). [Preprint].

  4. Kim, H. and Kottas, A. (2026). “Nonparametric Bayesian Modeling and Inference for Hawkes Processes.” (Under revision). [PDF].

Collaborative Research

  1. Bitting, R., Tseng, C., Giagtzis, A., Wyatt, A., McNair, C., Kim, H., Halabi, S., and Giri, V. (2026). “Patterns of Poly(ADP-ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans with Prostate Cancer.” Clinical Genitourinary Cancer, 24(7), 102640.

  2. Choi, T., Halabi, S., Kim, H., and Wu, Y. (2026). “Residual-Based Sieve Maximum Full Likelihood Estimation for the Proportional Hazards Model.” Communications in Statistics - Theory and Methods, 55(14), 4698–4715.

  3. Halabi, S., Luo, B., Yu, C., Rydzewska, L. H. M., Roy, A., Kim, H., Godolphin, P. J., Murphy, L., Carducci, M. A., Gravis, G., Sfumato, P., Boher, J. M., James, N. D., Tierney, J. F., Page, D., Sweeney, C., and Guo, S. (2026). “Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).” European Urology Focus, 12(3), 414–425.

  4. Gupta, S., Guo, S., Halabi, S., Yu, C., Kim, H., McKenzie, J., George, D. J., Nanus, D. M., Szmulewicz, R. Z., Danila, D. C., Luo, J., Antonarakis, E. S., and Armstrong, A. J. (2026). “Cytoplasmic versus Nuclear Localization of Androgen Receptor Splice Variant 7 as a Predictor of Benefit from Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer (PROPHECY Trial).” Prostate Cancer and Prostatic Diseases, 1–9.